JANUARY 4, 2024
The collaboration aims to deliver an innovative solution to improve overall patient treatment adherence and clinical outcomes. Both companies believe that patient experience in oncology can be improved with innovative subcutaneous injection devices and digital platforms. For pharmaceutical companies, this collaboration is an opportunity to offer a more patient-centric solution, and tackle potential challenges, such as treatment interruptions or discontinuations related to administration issues or adverse effects. This solution will also support the transition from intravenous to subcutaneous administration of oncology drugs.
You can read the press release below to learn more.
